On Monday, Sorrento Therapeutics Inc(NASDAQ:SRNE)’s shares inclined 9.40% to $16.29.
Sorrento Therapeutics, Inc. (SRNE) declared that it in addition to its wholly-owned partner TNK Therapeutics, Inc. have reached a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California. The exclusive licenses will cover the applications of the NanoVelcro CTC assay and its portfolio technologies for precision medicine diagnostics in conjunction with all cellular therapies and Sorrento antibody therapeutics.
The NanoVelcro Chip is a device capable of enriching, isolating, and identifying CTCs from peripheral blood of cancer patients. Coupled with downstream molecular assays, it enables the characterization of individually isolated CTCs, thus providing diagnostic information for the monitoring of real-time disease progression and tailoring individualized therapy solutions for cancer patients. The NanoVelcro Chip utilizes antibody-coated nanostructured substrates to capture CTCs with high efficiency. Once the CTCs are immobilized on the NanoVelcro Chips, laser capture microdissection technology allows for selective recovery of the CTCs with single-cell precision, virtually eliminating any trace of contamination from white blood cells that might complicate further downstream analysis. Finally, the isolated and purified CTCs are subjected to in-depth molecular characterization, counting mutational analysis, copy number variance, expression profiling, multi-color protein staining in addition to quantification of key phospho-proteins in signal transduction netoperates. These CTC-derived molecular signatures may assist doctors to implement personalized therapies targeting a patient’s unique cancer.
Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company primary therapeutic focus is oncology, counting the treatment of chronic cancer pain, in addition to developing therapeutic products for other indications, such as immunology and infectious diseases. Its lead product, Cynviloq, is polymeric, albumin-free nanoparticle paclitaxel formulation, approved and marketed in South Korea for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also accomplished Phase I, Phase II, and Phase III clinical trials, and post-marketing surveillance studies in MBC, NSCLC, ovarian, pancreatic, and bladder cancer.
National Retail Properties, Inc. (NYSE:NNN)’s shares gained 0.97% to $37.62.
National Retail Properties, Inc. (NNN), a real estate investment trust, recently declared its operating results for the quarter and six months ended June 30, 2015. Highlights comprise:
Second Quarter 2015 Highlights:
- FFO per share and Recurring FFO per share raised 10.0% over preceding year results
- AFFO per share raised 9.8% over preceding year results
- Portfolio occupancy is 98.8% at June 30, 2015, compriseent with March 31, 2015, and 98.6% at December 31, 2014
- Invested $147.8 million in 37 properties with an aggregate 669,000 square feet of gross leasable area at an initial cash yield of 7.1%
- Sold three properties for $2.2 million producing $30,000 of gains on sales
- Raised $38.7 million in net proceeds from the issuance of 983,317 common shares
National Retail Properties, Inc. is a publicly owned equity real estate investment trust. The firm acquires, owns, manages, and develops retail properties in the United States. It provides complete turn-key and built-to-suit development services counting market analysis, site selection and acquisition, entitlements, permitting, and construction administration.
At the end of Monday’s trade, Stratasys, Ltd. (NASDAQ:SSYS)‘s shares dipped -2.29% to $30.69.
Stratasys Ltd. (SSYS) declared financial results for the second quarter of 2015.
Q2-2015 Financial Results Summary:
- Revenue for the second quarter of 2015 was $182.3 million, contrast to $178.5 million for the same period last year;
- GAAP net loss for the second quarter was $22.9 million, or ($0.55) per diluted share, contrast to GAAP net loss of $173,000, or ($0.00) per diluted share, for the same period last year.
- Non-GAAP net income for the second quarter was $8 million, or $0.15 per diluted share, contrast to non-GAAP net income of $28.0 million, or $0.55 per diluted share, stated for the same period last year.
- The Company invested a net amount of $22.5 million in R&D projects (non-GAAP basis) during the second quarter, representing 12% of revenues.
Stratasys Ltd. provides additive manufacturing (AM) solutions for the creation of parts used in the processes of designing and manufacturing products; and for the direct manufacture of end parts. Its AM systems utilize its patented fused deposition modeling and inkjet-based PolyJet technologies to enable the production of prototypes, tools used for production and manufactured goods directly from three-dimensional (3D) CAD files or other 3D content. The company offers entry-level desktop 3D printers for idea and design development, a range of systems for rapid prototyping, and production systems for direct digital manufacturing under the Dimension, Objet, Fortus, Polyjet, SolidScape, and MakerBot brands.
Sierra Wireless, Inc. (USA) (NASDAQ:SWIR), ended its Monday’s trading session with -6.53% loss, and closed at $24.05.
Sierra Wireless, Inc. (SWIR) stated results for its second quarter, ending June 30, 2015. All results are stated in U.S. dollars and are prepared in accordance with United States generally accepted accounting principles (GAAP), except as otherwise indicated below.
GAAP RESULTS
- Gross margin was $50.9 million, or 32.3% of revenue, in the second quarter of 2015, contrast to $43.3 million, or 32.1% of revenue, in the second quarter of 2014.
- Operating expenses were $46.8 million and earnings from operations were $4.1 million in the second quarter of 2015, contrast to operating expenses of $49.6 million and a loss from operations of $6.3 million in the second quarter of 2014.
- Net earnings were $4.1 million, or $0.12 per diluted share, in the second quarter of 2015, contrast to a net loss of $8.2 million, or $0.26 per diluted share, in the second quarter of 2014.
Sierra Wireless, Inc., together with its auxiliaries, provides cellular wireless solutions to the machine-to-machine (M2M) and connected device markets in North America, Europe, and the Asia Pacific. It operates in two segments, Original Equipment Manufacturer (OEM) Solutions and Enterprise Solutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
